Literature DB >> 22054733

Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.

Nitin Jain1, Koen van Besien.   

Abstract

In the pre-tyrosine kinase (TKI) era, allogeneic stem cell transplant (allo-SCT) was the front-line treatment of choice for young patients with chronic myelogenous leukemia (CML). Today, imatinib is well established as front-line therapy for CML, with excellent long-term outcomes. This has changed the role of allo-SCT and the number of patients undergoing allo-SCT has declined dramatically. Allo-SCT is currently recommended for patients in accelerated/blast phase disease, those who have failed a second-generation TKI and those with TKI-resistant mutations such as T315I. The role of allo-SCT in the management of CML will require continual reappraisal as medical therapies continue to evolve. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22054733      PMCID： PMC3246008          DOI： 10.1016/j.hoc.2011.09.003

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  120 in total

1.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.

Authors:  S Giralt; E Estey; M Albitar; K van Besien; G Rondón; P Anderlini; S O'Brien; I Khouri; J Gajewski; R Mehra; D Claxton; B Andersson; M Beran; D Przepiorka; C Koller; S Kornblau; M Kørbling; M Keating; H Kantarjian; R Champlin
Journal:  Blood       Date:  1997-06-15       Impact factor: 22.113

2.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation.

Authors:  P L Weiden; K M Sullivan; N Flournoy; R Storb; E D Thomas
Journal:  N Engl J Med       Date:  1981-06-18       Impact factor: 91.245

3.  Collection, cryopreservation and subsequent viability of haemopoietic stem cells intended for treatment of chronic granulocytic leukaemia in blast-cell transformation.

Authors:  J M Goldman; K H Th'ng; D S Park; A S Spiers; R M Lowenthal; T Ruutu
Journal:  Br J Haematol       Date:  1978-10       Impact factor: 6.998

4.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Authors:  R H Collins; O Shpilberg; W R Drobyski; D L Porter; S Giralt; R Champlin; S A Goodman; S N Wolff; W Hu; C Verfaillie; A List; W Dalton; N Ognoskie; A Chetrit; J H Antin; J Nemunaitis
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

5.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.

Authors:  S Slavin; A Nagler; E Naparstek; Y Kapelushnik; M Aker; G Cividalli; G Varadi; M Kirschbaum; A Ackerstein; S Samuel; A Amar; C Brautbar; O Ben-Tal; A Eldor; R Or
Journal:  Blood       Date:  1998-02-01       Impact factor: 22.113

6.  Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia.

Authors:  J A Hansen; T A Gooley; P J Martin; F Appelbaum; T R Chauncey; R A Clift; E W Petersdorf; J Radich; J E Sanders; R F Storb; K M Sullivan; C Anasetti
Journal:  N Engl J Med       Date:  1998-04-02       Impact factor: 91.245

7.  Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation.

Authors:  R A Clift; C D Buckner; E D Thomas; K Doney; A Fefer; P E Neiman; J Singer; J Sanders; P Stewart; K M Sullivan; J Deeg; R Storb
Journal:  Lancet       Date:  1982-09-18       Impact factor: 79.321

8.  Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  A Gratwohl; J Hermans; J M Goldman; W Arcese; E Carreras; A Devergie; F Frassoni; G Gahrton; H J Kolb; D Niederwieser; T Ruutu; J P Vernant; T de Witte; J Apperley
Journal:  Lancet       Date:  1998-10-03       Impact factor: 79.321

9.  A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

Authors:  J Hasford; M Pfirrmann; R Hehlmann; N C Allan; M Baccarani; J C Kluin-Nelemans; G Alimena; J L Steegmann; H Ansari
Journal:  J Natl Cancer Inst       Date:  1998-06-03       Impact factor: 13.506

10.  Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience.

Authors:  I F Khouri; H M Kantarjian; M Talpaz; S Giralt; M O Rios; J P Hester; R E Champlin; A B Deisseroth
Journal:  Bone Marrow Transplant       Date:  1996-05       Impact factor: 5.483
View more
  5 in total

Review 1.  How we will treat chronic myeloid leukemia in 2016.

Authors:  Chetasi Talati; Evelena P Ontiveros; Elizabeth A Griffiths; Eunice S Wang; Meir Wetzler
Journal:  Blood Rev       Date:  2014-12-17       Impact factor: 8.250

Review 2.  Chronic myelogenous leukemia presenting with central nervous system infiltration, successfully treated with central nervous system-directed chemotherapy followed by allogeneic stem cell transplantation.

Authors:  Akira Chiba; Takashi Toya; Hideaki Mizuno; Junji Tokushige; Fumihiko Nakamura; Kumi Nakazaki; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2018-08-04       Impact factor: 2.490

3.  Characterization of Patients with Chronic Myeloid Leukemia Unresponsive to Tyrosine Kinase Inhibitors Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Franceli Ramos Carvalho; Joice Zuckermann; Alessandra Paz; Gustavo Fischer; Liane Esteves Daudt; Lisandra Della Costa Rigoni; Lúcia Silla; Laura Fogliatto; Simone Martins de Castro; Diogo André Pilger
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2017-01-01

4.  Implementing the EffTox dose-finding design in the Matchpoint trial.

Authors:  Kristian Brock; Lucinda Billingham; Mhairi Copland; Shamyla Siddique; Mirjana Sirovica; Christina Yap
Journal:  BMC Med Res Methodol       Date:  2017-07-20       Impact factor: 4.615

5.  An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States.

Authors:  Vivek Kumar; Mohit Garg; Neha Chaudhary; Abhinav Binod Chandra
Journal:  PeerJ       Date:  2018-02-12       Impact factor: 2.984
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.